Pfizer and BioNTech, makers of coronavirus vaccines, said Thursday that their product is effective against the Covid-19 variants that have emerged in the UK and South Africa.
In a statement, the two companies said that the “small differences” found in tests comparing the original virus with the recent versions do not appear to be leading to a significant reduction. in the effectiveness of the vaccine ”, reports AFP.
As previously reported, the Moderna coronavirus vaccine appears to be working against the newer and more infectious versions of Covid-19 found in the UK and South Africa.
Early laboratory tests suggested that antibodies induced by the Covid-19 vaccine can identify and fight the new variants.
However, more studies are needed to confirm that this is true for people who have been vaccinated.
Covaxin is effective on the UK virus strain of Covid-19
Meanwhile, a study by the Medical Research Council of India (ICMR) on Covaxin conducted in India shows a relative neutralization activity of the people who received the vaccine against the new variant RA.
An ICMR National Institute of Virology scientist performed the plaque reduction neutralization test using sera collected from the 26 who received the Bharat Biotech coronavirus (Covaxin) vaccine against the UK mutant virus.
“The relative neutralization activity of the sera vaccinated individuals against the UK variant and the heterologous pressure with equal efficacy have eliminated the uncertainty of a possible neutral escape,” a named document revealed. in bioRxiv in pre-printed version.
“We succeeded and removed the SARS-CoV-2 from UK retrievers in India with all signature variants of the variable UK,” the NIV-Pune scientist noted. near.
“We demonstrate the titers of neutralizing antibodies (Nab) to confirm the efficacy of the Covaxin vaccine candidate against SARS-CoV-2 UK-variant and one of the heterologous strains. Sera collected from 38 vaccine recipients, a a candidate received a Covaxin vaccine in a grade- II test on NAb titers equated a homologous strain and two heterologous strains by substituting the UK variable feature, ”the authors said.
“The average 50 per cent neutralization ratio of sera was found to be 0.8 and 0.9 compared to earlier SARS CoV-2 strains detected against UK mutant strain,” they said.
“It is clear that our study highlighted the relatively neutral activity of sera-vaccinated individuals against variable variants as well as heterologous SARS-CoV-2 sequences.”
“Importantly, sera from vaccine recipients could neutralize the different types of RA reducing the uncertainty of possible escape. It was encouraging from the data to neutralize antibodies that created in our laboratory that the native Covaxin would be expected after its release in the vaccine program.work against the new UK version.It is unlikely to be able to mutate the potential benefits reduce the vaccination, “he said.
The new variables have spread rapidly in several countries.
In India, the number of people who have tested positive for the new UK version of Covid-19 has climbed to 153, Union Health Minister Harsh Vardhan said on Thursday.
By entering groups